Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial

被引：0
|
作者：
Jin, Y. [1 ]
Yu, X. [1 ]
Fan, Y. [1 ]
He, X. Q. [1 ]
Lin, C. [1 ]
Hong, W. [1 ]
Gu, C. [1 ]
机构：
[1] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
497P
引用
收藏
页码：S1656 / S1657
页数：2
相关论文
共 50 条
  • [21] Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial
    Zhou, Na
    Zhang, Chuantao
    Liu, Dong
    Liu, Kewei
    Wang, Guanqun
    Zhu, Hua
    Zhang, Jianli
    Jiang, Man
    Liu, Ning
    Zhang, Xiaochun
    ONCOLOGIST, 2021, 26 (03): : E374 - E381
  • [22] Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study
    Chen, L. K.
    Chen, J.
    Li, M. C.
    Yu, H.
    Zhang, B. S.
    Hou, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S48 - S49
  • [23] A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC
    Han, B.
    Chen, J.
    Xie, Q.
    Yao, W.
    Shi, H.
    Zhao, Y.
    Song, W.
    Jin, X.
    Wang, Z.
    Li, B.
    Xia, Y.
    Jiao, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S650 - S650
  • [24] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [25] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
  • [26] Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
    Xu, Qin
    Chen, Chuanben
    Sun, Yang
    Huang, Zhangzhou
    Lin, Yibin
    Liu, Jing
    Li, Li
    Li, Zirong
    Pan, Junping
    Chen, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Sintilimab combined sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase II study.
    Wang, Jiabei
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16182 - E16182
  • [28] Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced soft tissue sarcoma: A single-arm phase
    Luo, Z.
    Liu, X.
    Zhang, X.
    He, X.
    Zhang, S.
    Yan, W.
    Chen, Y.
    Wang, C.
    Xu, Y.
    Yu, L.
    Wang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1401 - S1401
  • [29] Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
    Liu, Dechun
    Yan, Tao
    Zhang, Qian
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S89 - S90
  • [30] Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Zhang, Qiyi
    Liu, Xingyu
    Wei, Shumei
    Zhang, Lufei
    Tian, Yang
    Gao, Zhenzhen
    Jin, Ming
    Yan, Sheng
    FRONTIERS IN ONCOLOGY, 2021, 11
12345